BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2007

View Archived Issues

Positive results for Regeneron's proof-of-concept study of rilonacept for gout / News in Context

Read More

Novel CXCR2 antagonist useful in models of acute and chronic inflammation

Read More

GenVec signs CRADA for malaria vaccine development

Read More

ProMetic Life Sciences expands PBI-1402 program to include cancer-related anemia

Read More

Positive results for Renovo's phase II trial of Juvista for treatment of wounds and scars

Read More

New antipsychotic, antidepressive and anxiolytic agents cited in patent literature

Read More

CRT, UCL and Novozymes to codevelop novel anticancer therapeutics

Read More

FDA opens Corcept's IND for Corlux for Cushing's syndrome allowing initiation of phase III study

Read More

Estrogen-dependent breast cancer growth in vivo suppressed by KW-2581

Read More

New compounds for treatment of HCV infection revealed

Read More

Recent patents impart new therapeutic agents for cancer

Read More

FDA Advisory Committees reaffirm current dosing practices for ESAs

Read More

Inhibitex licenses HIV integrase and hepatitis C polymerase inhibitors from UGARF

Read More

Phenomix begins phase IIb trial of PHX-1149 for type 2 diabetes

Read More

Phosphagenics to initiate phase II trials of TMP/Insulin for diabetes

Read More

BioSante and FDA reach agreement on LibiGel development requirements

Read More

Update on Aspreva and Roche's development of CellCept for lupus nephritis

Read More

Nventa begins phase I trial of HspE7 dosed with an adjuvant for CIN

Read More

Positive results for Chelsea's new formulation of CH-1504 for RA

Read More

Trubion reports preliminary analysis of phase IIb trial of TRU-015 for RA

Read More

New drug targets in neuropathic pain described

Read More

Minocycline shows neuroprotection in animal models of Alzheimer's disease

Read More

Pivotal phase III prophylactic HAE trial of Cinryze meets primary endpoint

Read More

FDA grants Metabasis' MB-07133 orphan drug designation for HCC

Read More

Novartis launches daptomycin for MSSA and MRSA bloodstream and heart infections

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing